ALGS
Aligos Therapeutics, Inc.
Price Chart
Latest Quote
$7.95
Current Price| Previous Close | $8.07 |
| Open | $7.98 |
| Day High | $8.39 |
| Day Low | $7.76 |
| Volume | 80,795 |
Stock Information
| Shares Outstanding | 5.35M |
| Total Debt | $6.07M |
| Cash Equivalents | $99.10M |
| Revenue | $2.65M |
| Net Income | $-86.46M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $48.92M |
| EPS (TTM) | $-13.54 |
| Exchange | NCM |
đ Custom Metrics & Score
Score: 19/42| Debt to Equity | -0.29 |
| Debt to Earnings | -0.06 |
| Current Ratio | 2.86 |
| Quick Ratio | 2.62 |
| Avg Revenue Growth | -2.37% |
| Profit Margin | -3326.01% |
| Return on Equity | 452.87% |
| Avg FCF Growth | -7.65% |
| FCF Yield | -165.31% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $7.95 | 80,900 |
| 2026-01-30 | $8.07 | 40,100 |
| 2026-01-29 | $8.11 | 49,500 |
| 2026-01-28 | $8.06 | 79,900 |
| 2026-01-27 | $8.59 | 94,300 |
| 2026-01-26 | $8.39 | 78,300 |
| 2026-01-23 | $8.12 | 158,800 |
| 2026-01-22 | $8.54 | 123,700 |
| 2026-01-21 | $8.00 | 81,000 |
| 2026-01-20 | $8.01 | 83,600 |
| 2026-01-16 | $7.94 | 65,600 |
| 2026-01-15 | $8.26 | 87,000 |
| 2026-01-14 | $9.05 | 87,500 |
| 2026-01-13 | $9.24 | 47,500 |
| 2026-01-12 | $8.71 | 110,000 |
| 2026-01-09 | $9.00 | 88,900 |
| 2026-01-08 | $10.33 | 88,800 |
| 2026-01-07 | $9.65 | 64,300 |
| 2026-01-06 | $8.76 | 23,100 |
| 2026-01-05 | $8.41 | 145,900 |
About Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-Ã agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
đ° Latest News
Here's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash Wisely
Simply Wall St. âĸ 2026-01-07T14:35:56Z
Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect?
Zacks âĸ 2025-09-08T21:04:15Z
Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia
Zacks âĸ 2025-09-01T16:30:00Z
RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study
Zacks âĸ 2025-08-21T15:13:00Z
Wall Street Analysts Predict a 983.24% Upside in Aligos Therapeutics (ALGS): Here's What You Should Know
Zacks âĸ 2025-08-19T13:55:02Z
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
Zacks âĸ 2025-08-14T15:11:00Z
Aligos commences dosing in Phase II trial for chronic hepatitis B treatment
Clinical Trials Arena âĸ 2025-08-14T09:51:38Z
Aligos Therapeutics Second Quarter 2025 Earnings: Beats Expectations
Simply Wall St. âĸ 2025-08-09T12:29:11Z
Aligos Therapeutics, Inc. (ALGS) Reports Q2 Loss, Misses Revenue Estimates
Zacks âĸ 2025-08-06T22:00:02Z
Aligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash Wisely
Simply Wall St. âĸ 2025-07-31T13:48:26Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $3,945,000 | $15,529,000 | $13,907,000 | $4,359,000 |
| Operating Revenue | $3,945,000 | $15,529,000 | $13,907,000 | $4,359,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Expenses | $93,099,000 | $103,656,000 | $111,487,000 | $132,680,000 |
| Other Income Expense | $-46,132,000 | $-2,169,000 | - | - |
| Net Non Operating Interest Income Expense | $4,406,000 | $3,412,000 | $1,640,000 | $132,000 |
| Total Other Finance Cost | $-4,406,000 | $-3,412,000 | - | - |
| Operating Expense | $93,099,000 | $103,656,000 | $111,487,000 | $132,680,000 |
| General And Administrative Expense | $22,830,000 | $30,616,000 | $26,410,000 | $28,527,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-131,211,000 | $-87,679,000 | $-96,046,000 | $-128,332,000 |
| Net Interest Income | $4,406,000 | $3,412,000 | $1,640,000 | $132,000 |
| Normalized Income | $-94,766,720 | $-85,965,490 | $-96,046,000 | $-128,332,000 |
| Net Income From Continuing And Discontinued Operation | $-131,211,000 | $-87,679,000 | $-96,046,000 | $-128,332,000 |
| Total Operating Income As Reported | $-89,154,000 | $-88,127,000 | $-97,580,000 | $-128,321,000 |
| Net Income Common Stockholders | $-131,211,000 | $-87,679,000 | $-96,046,000 | $-128,332,000 |
| Net Income | $-131,211,000 | $-87,679,000 | $-96,046,000 | $-128,332,000 |
| Net Income Including Noncontrolling Interests | $-131,211,000 | $-87,679,000 | $-96,046,000 | $-128,332,000 |
| Net Income Continuous Operations | $-131,211,000 | $-87,679,000 | $-96,046,000 | $-128,332,000 |
| Pretax Income | $-130,880,000 | $-86,884,000 | $-95,940,000 | $-128,189,000 |
| Operating Income | $-89,154,000 | $-88,127,000 | $-97,580,000 | $-128,321,000 |
| Interest Income | - | $1,243,000 | $1,640,000 | $132,000 |
| Interest Income Non Operating | - | $1,243,000 | $1,640,000 | $132,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-20.94 | $-34.20 | $-56.25 | $-80.50 |
| Basic EPS | $-20.94 | $-34.20 | $-56.25 | $-80.50 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $-9,687,720 | $-455,490 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-40,400,000 | $-82,889,000 | $-93,905,000 | $-124,543,000 |
| Total Unusual Items | $-46,132,000 | $-2,169,000 | - | - |
| Total Unusual Items Excluding Goodwill | $-46,132,000 | $-2,169,000 | - | - |
| Reconciled Depreciation | $2,622,000 | $3,069,000 | $3,675,000 | $3,778,000 |
| EBITDA (Bullshit earnings) | $-86,532,000 | $-85,058,000 | $-93,905,000 | $-124,543,000 |
| EBIT | $-89,154,000 | $-88,127,000 | $-97,580,000 | $-128,321,000 |
| Diluted Average Shares | $6,264,612 | $2,563,470 | $1,707,809 | $1,594,216 |
| Basic Average Shares | $6,264,612 | $2,563,470 | $1,707,809 | $1,594,216 |
| Diluted NI Availto Com Stockholders | $-131,211,000 | $-87,679,000 | $-96,046,000 | $-128,332,000 |
| Tax Provision | $331,000 | $795,000 | $106,000 | $143,000 |
| Gain On Sale Of Security | $-46,132,000 | $-2,169,000 | - | - |
| Research And Development | $70,269,000 | $73,040,000 | $85,077,000 | $104,153,000 |
| Selling General And Administration | $22,830,000 | $30,616,000 | $26,410,000 | $28,527,000 |
| Other Gand A | $22,830,000 | $30,616,000 | $26,410,000 | $28,527,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $-28,973,000 | $92,080,000 | $103,900,000 | $184,731,000 |
| Total Assets | $70,094,000 | $151,527,000 | $146,693,000 | $235,369,000 |
| Total Non Current Assets | $7,953,000 | $10,443,000 | $13,148,000 | $30,945,000 |
| Other Non Current Assets | $627,000 | $625,000 | $634,000 | $866,000 |
| Current Assets | $62,141,000 | $141,084,000 | $133,545,000 | $204,424,000 |
| Other Current Assets | $5,092,000 | $5,310,000 | $7,603,000 | $13,526,000 |
| Restricted Cash | $110,000 | $70,000 | $115,000 | $164,000 |
| Cash Cash Equivalents And Short Term Investments | $56,939,000 | $135,704,000 | $125,827,000 | $190,734,000 |
| Cash And Cash Equivalents | $36,997,000 | $135,704,000 | $81,347,000 | $186,816,000 |
| Cash Equivalents | $36,997,000 | $135,704,000 | $81,347,000 | $186,816,000 |
| Investmentin Financial Assets | - | - | $0 | $15,110,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $8,375,000 | $11,138,000 | $12,574,000 | $14,455,000 |
| Long Term Debt And Capital Lease Obligation | $4,917,000 | $7,899,000 | $9,431,000 | $11,548,000 |
| Current Debt And Capital Lease Obligation | $3,458,000 | $3,239,000 | $3,143,000 | $2,907,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $99,067,000 | $59,447,000 | $42,793,000 | $50,638,000 |
| Total Non Current Liabilities Net Minority Interest | $77,330,000 | $35,541,000 | $9,664,000 | $11,681,000 |
| Other Non Current Liabilities | $46,000 | $46,000 | - | $133,000 |
| Derivative Product Liabilities | $72,367,000 | $27,596,000 | $0 | - |
| Current Liabilities | $21,737,000 | $23,906,000 | $33,129,000 | $38,957,000 |
| Current Deferred Liabilities | $151,000 | $1,308,000 | $9,210,000 | $7,641,000 |
| Payables And Accrued Expenses | $11,741,000 | $12,686,000 | $14,413,000 | $21,804,000 |
| Payables | $4,042,000 | $3,028,000 | $12,940,000 | $20,569,000 |
| Other Payable | $1,471,000 | $511,000 | $8,203,000 | $17,554,000 |
| Accounts Payable | $2,571,000 | $2,517,000 | $4,737,000 | $3,015,000 |
| Non Current Deferred Liabilities | - | $0 | $233,000 | $0 |
| Other Current Liabilities | - | - | $66,000 | $276,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $-28,973,000 | $92,080,000 | $103,900,000 | $184,731,000 |
| Total Equity Gross Minority Interest | $-28,973,000 | $92,080,000 | $103,900,000 | $184,731,000 |
| Stockholders Equity | $-28,973,000 | $92,080,000 | $103,900,000 | $184,731,000 |
| Gains Losses Not Affecting Retained Earnings | $451,000 | $545,000 | $401,000 | $452,000 |
| Other Equity Adjustments | $451,000 | $545,000 | $401,000 | $452,000 |
| Retained Earnings | $-618,008,000 | $-486,797,000 | $-399,118,000 | $-303,072,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $3,864,436 | $3,003,876 | $1,716,919 | $1,707,609 |
| Share Issued | $3,864,436 | $3,003,876 | $1,716,919 | $1,707,609 |
| Tangible Book Value | $-28,973,000 | $92,080,000 | $103,900,000 | $184,731,000 |
| Invested Capital | $-28,973,000 | $92,080,000 | $103,900,000 | $184,731,000 |
| Working Capital | $40,404,000 | $117,178,000 | $100,416,000 | $165,467,000 |
| Capital Lease Obligations | $8,375,000 | $11,138,000 | $12,574,000 | $14,455,000 |
| Total Capitalization | $-28,973,000 | $92,080,000 | $103,900,000 | $184,731,000 |
| Additional Paid In Capital | $588,576,000 | $578,325,000 | $502,613,000 | $487,347,000 |
| Capital Stock | $8,000 | $7,000 | $4,000 | $4,000 |
| Common Stock | $8,000 | $7,000 | $4,000 | $4,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $4,917,000 | $7,899,000 | $9,431,000 | $11,548,000 |
| Current Deferred Revenue | $151,000 | $1,308,000 | $9,210,000 | $7,641,000 |
| Current Capital Lease Obligation | $3,458,000 | $3,239,000 | $3,143,000 | $2,907,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $6,387,000 | $6,673,000 | $6,297,000 | $6,329,000 |
| Current Accrued Expenses | $7,699,000 | $9,658,000 | $1,473,000 | $1,235,000 |
| Net PPE | $7,326,000 | $9,818,000 | $12,514,000 | $14,969,000 |
| Accumulated Depreciation | $-11,782,000 | $-10,755,000 | $-9,568,000 | $-7,262,000 |
| Gross PPE | $19,108,000 | $20,573,000 | $22,082,000 | $22,231,000 |
| Leases | $6,101,000 | $6,101,000 | $6,087,000 | $5,940,000 |
| Construction In Progress | $4,000 | $4,000 | $22,000 | $22,000 |
| Other Properties | $10,939,000 | $12,389,000 | $13,877,000 | $14,498,000 |
| Machinery Furniture Equipment | $2,064,000 | $2,079,000 | $2,096,000 | $1,771,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $19,942,000 | $0 | $44,480,000 | $3,918,000 |
| Non Current Deferred Revenue | - | $0 | $233,000 | $0 |
| Investments And Advances | - | - | $0 | $15,110,000 |
| Available For Sale Securities | - | - | - | $15,110,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-80,873,000 | $-79,016,000 | $-80,332,000 | $-116,554,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-80,743,000 | $-78,997,000 | $-79,389,000 | $-115,662,000 |
| Cash Flow From Continuing Operating Activities | $-80,743,000 | $-78,997,000 | $-79,389,000 | $-115,662,000 |
| Operating Gains Losses | $46,132,000 | $2,186,000 | - | - |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-130,000 | $-19,000 | $-943,000 | $-892,000 |
| Investing Cash Flow | $-18,279,000 | $44,981,000 | $-26,293,000 | $3,022,000 |
| Cash Flow From Continuing Investing Activities | $-18,279,000 | $44,981,000 | $-26,293,000 | $3,022,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $0 | $17,443,000 | $0 | $78,584,000 |
| Financing Cash Flow | $355,000 | $88,328,000 | $164,000 | $78,677,000 |
| Cash Flow From Continuing Financing Activities | $355,000 | $88,328,000 | $164,000 | $78,677,000 |
| Net Common Stock Issuance | $0 | $17,443,000 | $0 | $78,584,000 |
| Common Stock Issuance | $0 | $17,443,000 | $0 | $78,584,000 |
| Net Other Financing Charges | - | - | - | $-875,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-83,000 | $-96,000 | $-61,000 | $-79,000 |
| End Cash Position | $37,107,000 | $135,774,000 | $81,462,000 | $186,980,000 |
| Beginning Cash Position | $135,774,000 | $81,462,000 | $186,980,000 | $220,943,000 |
| Changes In Cash | $-98,667,000 | $54,312,000 | $-105,518,000 | $-33,963,000 |
| Proceeds From Stock Option Exercised | $438,000 | $70,981,000 | $225,000 | $1,047,000 |
| Net Issuance Payments Of Debt | $-83,000 | $-96,000 | $-61,000 | $-79,000 |
| Net Long Term Debt Issuance | $-83,000 | $-96,000 | $-61,000 | $-79,000 |
| Long Term Debt Payments | $-83,000 | $-96,000 | $-61,000 | $-79,000 |
| Net Investment Purchase And Sale | $-18,149,000 | $45,000,000 | $-25,350,000 | $3,914,000 |
| Sale Of Investment | $90,000,000 | $45,011,000 | $78,915,000 | $23,000,000 |
| Purchase Of Investment | $-108,149,000 | $-11,000 | $-104,265,000 | $-19,086,000 |
| Net PPE Purchase And Sale | $-130,000 | $-19,000 | $-943,000 | $-892,000 |
| Purchase Of PPE | $-130,000 | $-19,000 | $-943,000 | $-892,000 |
| Change In Working Capital | $-4,955,000 | $-9,525,000 | $-1,552,000 | $-4,651,000 |
| Change In Other Working Capital | $-1,157,000 | $-8,135,000 | $2,502,000 | $-4,359,000 |
| Change In Other Current Liabilities | $-2,680,000 | $-2,386,000 | $-1,952,000 | $-1,649,000 |
| Change In Other Current Assets | $216,000 | $2,297,000 | $5,316,000 | $-8,072,000 |
| Change In Payables And Accrued Expense | $-1,334,000 | $-1,301,000 | $-7,418,000 | $9,429,000 |
| Change In Accrued Expense | $-1,388,000 | $918,000 | $-9,140,000 | $9,742,000 |
| Change In Payable | $54,000 | $-2,219,000 | $1,722,000 | $-313,000 |
| Change In Account Payable | $54,000 | $-2,219,000 | $1,722,000 | $-313,000 |
| Stock Based Compensation | $8,452,000 | $12,652,000 | $14,693,000 | $13,457,000 |
| Asset Impairment Charge | $0 | $724,000 | $0 | - |
| Amortization Of Securities | $-1,783,000 | $-424,000 | $-159,000 | $86,000 |
| Depreciation Amortization Depletion | $2,622,000 | $3,069,000 | $3,675,000 | $3,778,000 |
| Depreciation And Amortization | $2,622,000 | $3,069,000 | $3,675,000 | $3,778,000 |
| Depreciation | $2,622,000 | $3,069,000 | $3,675,000 | $3,778,000 |
| Gain Loss On Investment Securities | $46,132,000 | $2,169,000 | - | - |
| Net Income From Continuing Operations | $-131,211,000 | $-87,679,000 | $-96,046,000 | $-128,332,000 |
| Interest Paid Supplemental Data | - | - | $0 | $0 |
| Income Tax Paid Supplemental Data | - | - | $0 | $0 |